Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:GPCR News 8 December 2025 - 15 January 2026

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

New York, Jan 15, 2026, 13:24 EST — Regular session Pfizer shares edged up roughly 0.3% to $25.67 on Thursday, finding footing after a volatile start to the year. Investors mulled over renewed discussions on U.S. vaccine policy alongside Pfizer’s growth strategy. The stock fluctuated between $25.26 and $25.67, with about 22.3 million shares changing hands. Why it matters now: vaccine makers face fresh political and demand challenges in the U.S. Sanofi CEO Paul Hudson warned of near-term “softness” in vaccine uptake, blaming “misinformation.” Pfizer CEO Albert Bourla expressed being “seriously frustrated,” labeling the trend as “political and antivax,” Reuters
15 January 2026
·····
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

New York, January 14, 2026, 13:46 EST — Regular session Shares of Structure Therapeutics (GPCR) jumped roughly 7.5% Wednesday, as traders returned to small-cap obesity drugmakers. The stock climbed to $83.76, trading over 1 million shares. This shift is crucial as investors wager the weight-loss craze will move from weekly injections to pills, reshaping the buyout landscape. A Novo Nordisk executive told Reuters that oral pills might claim “a third-plus” of the GLP-1 market by 2030. (Reuters) Deal rumors picked up steam on Wednesday after a Bloomberg report, highlighted by TheFly, quoted Novo Nordisk CEO Mike Doustdar saying, “We’re in
14 January 2026
········
Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

NEW YORK, Jan 13, 2026, 12:18 EST — Regular session Shares of Structure Therapeutics climbed roughly 14% on Tuesday, adding to the stock’s recent swings. The move came as investors took a fresh look at the company’s newly announced patent licensing deal with Roche’s Genentech. (https://www.reuters.com/markets/companies/GPCR.O) This shift is significant as major drugmakers ramp up their push for obesity pills. Investors have been flocking to smaller, riskier companies poised to gain if these treatments capture a larger slice of the market than previously anticipated. At this week’s J.P. Morgan Healthcare Conference in San Francisco, Novo Nordisk said pills could account
13 January 2026
······
Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics Inc. (NASDAQ: GPCR) is ending 2025 in the middle of one of biotech’s hottest battlegrounds: oral weight-loss medicines. As of Dec. 23, 2025, GPCR shares were trading around $67.50 in U.S. session data, after a volatile stretch driven by blockbuster obesity-trial headlines, a major equity financing, and a wave of analyst price-target updates. Below is a comprehensive roundup of the latest news, forecasts, and analysis available as of 23.12.2025, and what investors are watching next. What is Structure Therapeutics, and why does GPCR trade like a headline detector? Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule
23 December 2025
·····
Structure Therapeutics (GPCR) Stock: Why Shares Are Sliding on Dec. 16, 2025 After Breakout Obesity Pill Data and a $747.5M Offering

Structure Therapeutics (GPCR) Stock: Why Shares Are Sliding on Dec. 16, 2025 After Breakout Obesity Pill Data and a $747.5M Offering

Structure Therapeutics Inc. (NASDAQ: GPCR) is having a classic biotech moment on Tuesday, December 16, 2025: big catalyst, big financing, and now big volatility. Shares were down about 6% in Tuesday trading, recently around $60.73, after swinging between roughly $58.95 and $65.69 intraday. The pullback comes just days after the company reported positive topline Phase 2b results for its oral obesity candidate aleniglipron (GSBR-1290)—news that sparked a surge—followed immediately by an upsized equity raise that ultimately brought in about $747.5 million in gross proceeds. GlobeNewswire+1 Below is a detailed, up-to-date breakdown of the latest GPCR stock news (as of 16.12.2025),
16 December 2025
····
Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics Inc. (NASDAQ: GPCR) has suddenly become one of the most talked‑about obesity‑drug names on Wall Street. As of mid‑day on December 9, 2025, Structure Therapeutics stock was trading around $69.98, up roughly 100% in a single session after the company unveiled strong mid‑stage data for its once‑daily oral GLP‑1 obesity pill, aleniglipron. GlobeNewswire+2Investors+2 Over the past six months, GPCR has already delivered a multi‑bagger move, with one analyst note calculating a ~241% gain even before today’s opening bell. The stock now sits near its 52‑week high, with a 52‑week range of about $13.22 to $94.90 and a market
9 December 2025
····
Structure Therapeutics (NASDAQ: GPCR) Stock Explodes on Obesity Pill Data and $500M Offering: Latest News and Forecasts as of December 9, 2025

Structure Therapeutics (NASDAQ: GPCR) Stock Explodes on Obesity Pill Data and $500M Offering: Latest News and Forecasts as of December 9, 2025

Snapshot: Where Structure Therapeutics Stock Stands Today Structure Therapeutics Inc. (NASDAQ: GPCR) has suddenly moved from niche obesity biotech to front‑page market story. As of December 9, 2025, GPCR is trading around $69.98, up roughly 102% in a single session compared with its previous close near $34.56. The stock’s intraday range on December 8 ran from $44.74 to $94.90, marking a new 52‑week high, and lifting its market capitalization to about $4.25 billion.StockAnalysis+1 This explosive move followed positive Phase 2b trial data for the company’s oral GLP‑1 obesity drug aleniglipron and the announcement of a proposed $500 million public offering
9 December 2025
····
Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly and Company (NYSE: LLY) spent Monday, December 8, 2025, digesting a wave of news: a major reimbursement win for Mounjaro in China, a 15% dividend hike, new leukemia drug data, and the return of Nobel laureate Carolyn Bertozzi to its board. At the same time, intensifying competition and price cuts in the weight‑loss drug market kept pressure on the stock. By the closing bell, Lilly shares were trading just under the psychologically important $1,000 level, still near a trillion‑dollar valuation but roughly 10% below recent highs. StockAnalysis Key takeaways for LLY before the December 9, 2025 open How
9 December 2025
·······
Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics Inc. (NASDAQ: GPCR) just turned a long‑anticipated clinical readout into a full‑blown stock market event. On Monday, December 8, 2025, the company released positive topline data from its ACCESS program for aleniglipron (GSBR‑1290), a once‑daily oral GLP‑1 receptor agonist for obesity. The market response was immediate: GPCR closed at $69.46, up about 101% on the day, after trading between $24.83 and an intraday high of $94.90. That move vaulted Structure into the front rank of the oral obesity drug race and forced investors, analysts and competitors to update their models in real time. Who is Structure Therapeutics and
8 December 2025
·····
Biggest Stock Gainers Today: Biotech Breakouts and IBM–Confluent Deal Lead U.S. Market Movers (December 8, 2025)

Biggest Stock Gainers Today: Biotech Breakouts and IBM–Confluent Deal Lead U.S. Market Movers (December 8, 2025)

U.S. stocks traded mostly flat on Monday as Wall Street headed into a crucial Federal Reserve meeting, but under the surface the tape was anything but quiet. While the S&P 500 and Dow Jones Industrial Average hovered around unchanged and the Nasdaq 100 eked out a small gain, small‑cap and high‑beta names ripped higher, led by a wave of biotech catalysts and a blockbuster AI‑data takeover. According to StockAnalysis.com’s real‑time “Gainers Today” screen, Cemtrex, Structure Therapeutics, Wave Life Sciences, Fulcrum Therapeutics and iBio sat atop the leaderboard by early afternoon, each posting gains of nearly 50% or more. Many of
8 December 2025
···········

Stock Market Today

Carvana stock jumps 5% to $403.67 — here’s what CVNA traders are watching next

Carvana stock jumps 5% to $403.67 — here’s what CVNA traders are watching next

7 February 2026
Carvana shares rose 5.21% Friday to $403.67, rebounding after recent volatility sparked by a short-seller report from Gotham City Research. The company denied allegations of overstated earnings and undisclosed ties to DriveTime. Carvana will report Q4 and full-year 2025 results after markets close on Feb. 18. The January U.S. CPI report is scheduled for Feb. 13.
Confluent stock hugs IBM’s $31 bid — here’s what investors watch next week

Confluent stock hugs IBM’s $31 bid — here’s what investors watch next week

7 February 2026
Confluent shares closed at $30.57 Friday, 43 cents below IBM’s $31-per-share cash offer, ahead of key events next week. The company will report earnings Feb. 11 without a call or outlook, and shareholders vote on the merger Feb. 12. Confluent disclosed 17 demand letters and two lawsuits over proxy disclosures but denies wrongdoing. The IBM deal values Confluent at $11 billion.
Go toTop